Valuation: NEOVACS SA

Market Cap 4.09T 4.65T 3.87T 3.51T 6.59T 4L 6.62T 46.3T 17.88T 2L 17.46T 17.08T 7L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.19Cr -3L -22.76L -9L -1.12Cr -9L -8L -3.6Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 41.49T
+0.24%+4.26%+12.89%+37.88% 4.91TCr
+0.22%+0.40%+50.91%+37.06% 4.46TCr
-1.58%+4.66%+359.34%+614.38% 4.32TCr
+1.70%+0.36%+12.56%+99.27% 4.17TCr
+0.51%-1.71%+5.18%+46.87% 2.99TCr
-0.48%-1.32%+23.98%+150.01% 1.72TCr
+0.08%+9.03%+8.41% - 1.54TCr
-2.39%-2.68%+26.38%+43.63% 1.55TCr
+1.97%-3.17% - - 1.51TCr
Average +0.03%+1.85%+62.46%+147.01% 3.02TCr
Weighted average by Cap. +0.09%+2.26%+78.21%+161.13%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.82Cr 9L 60.39L 23.32L 2.97Cr 22.77L 22.28L 9.55Cr 4L 5L 4L 4L 7L 4.74Cr 7L 49.13L 18.97L 2.42Cr 18.52L 18.12L 7.77Cr
Net income -87.43L -99.41L -82.68L -74.99L -1.41Cr -95Cr -1.42Cr -9.9Cr -3.82Cr -49Cr -3.73Cr -3.65Cr -156.48Cr -3.29Cr -3.74Cr -3.11Cr -2.82Cr -5.3Cr -359.24Cr -5.33Cr -37Cr -14Cr -183.31Cr -14Cr -14Cr -589.07Cr
Net Debt -2L -3L -2L -2L -4L -2.58Cr -4L -26.78L -10.34L -1.32Cr -10.1L -10L -4.23Cr -2L -2L -2L -2L -3L -2.24Cr -3L -23.22L -9L -1.14Cr -9L -9L -3.67Cr
Logo NEOVACS SA
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-